CrossBridge Bio Secures $15 Million CPRIT Grant to Advance Novel Dual-Payload ADC CBB-120 Targeting TROP-2
核心洞察
CrossBridge Bio (搜索) received a $15 million grant from the Cancer Prevention and Research Institute of Texas (搜索) to advance CBB-120, its lead dual-payload antibody-drug conjugate targeting TROP-2 (搜索), into first-in-human studies.
CBB-120 combines topoisomerase-1 (搜索) inhibitor and ATR inhibitor payloads within a single ADC molecule using proprietary branched tripeptide linkers, designed to overcome tumor resistance and heterogeneity.
The funding will support completion of GLP toxicology studies, manufacturing scale-up, and analytical development to prepare for an IND filing in 2026.
CrossBridge Bio (搜索) announced it has secured a $15 million grant from the Cancer Prevention and Research Institute of Texas (搜索) (CPRIT) to advance CBB-120, its lead dual-payload antibody-drug conjugate (ADC) targeting TROP-2 (搜索), into clinical development. The award will support completion of IND-enabling activities and advancement into first-in-human studies.
Innovative Dual-Payload Platform Technology
CrossBridge Bio (搜索)'s proprietary platform integrates branched tripeptide linkers (EGCit) with a dual-payload design that enables precise delivery of synergistic topoisomerase-1 (搜索) inhibitor and ATR inhibitor payloads within a single ADC molecule. This architecture is engineered to deliver deeper, more durable responses and to overcome tumor resistance and heterogeneity – key limitations of earlier-generation ADCs.
The company's approach represents a significant advancement in ADC technology, addressing the challenge of tumor resistance that has limited the effectiveness of approved ADC therapies. By combining two complementary mechanisms of action in a single molecule, CBB-120 aims to provide safer, more durable responses for patients, including those resistant to current ADC treatments.
Compelling Preclinical Results
CBB-120 has generated compelling preclinical data demonstrating potent and durable antitumor activity, including in models resistant to standard-of-care ADCs. The program was recently featured at the 2025 World ADC Conference, where it became the most attended non-plenary session in the event's history, underscoring broad scientific interest in the platform and program.
Clinical Development Timeline
The CPRIT award will enable CrossBridge Bio (搜索) to complete GLP toxicology studies, scale up manufacturing, finalize analytical development, and prepare for an IND filing in 2026. This funding represents a critical milestone in advancing the novel dual-payload ADC technology toward clinical testing.
"We are honored to receive CPRIT's support as we advance CBB-120 toward the clinic," said Michael Torres, Ph.D., Chief Executive Officer of CrossBridge Bio (搜索). "This grant is a strong validation of the innovation behind our dual-payload platform and reflects the importance of bringing new treatment options to patients facing difficult-to-treat cancers. CPRIT's support allows us to accelerate development with the urgency this opportunity deserves."
Dan Pereira, Ph.D., Chief Scientific Officer of CrossBridge Bio (搜索), emphasized the comprehensive nature of their scientific approach: "CBB-120 showcases the full strength of our scientific approach – dual-payload engineering, branched linker chemistry, and precision delivery. We're excited to build on the momentum from our World ADC recognition and move this program into clinical development, where we hope it will make a meaningful impact for patients with limited options."
Significant Funding Support
The Cancer Prevention and Research Institute of Texas (搜索) (CPRIT) is one of the world's largest public funders of cancer (搜索) research and prevention. Since 2009, CPRIT has awarded more than $3 billion in grants to support scientific innovation, product development, and evidence-based cancer prevention initiatives across Texas.
CrossBridge Bio (搜索) is a biotechnology company based in Houston, Texas, focused on developing next-generation dual-payload antibody-drug conjugates to overcome tumor resistance and heterogeneity. The company's proprietary EGCit branched linker technology enables precise, stable, and efficient payload delivery for improved therapeutic index.